Press Release: Sanofi to acquire Qunol®, a fast-growing U.S. brand in the healthy aging segment
28 Julho 2023 - 02:32AM
Sanofi to acquire Qunol®, a fast-growing U.S.
brand in the healthy aging segment
- Transaction brings Qunol®, a
trusted, profitable double-digit growth and market-leading brand in
health & wellness to Sanofi’s CHC U.S. portfolio
- Addition of Qunol’s CoQ10 and Turmeric
products strengthens Sanofi’s CHC Vitamin, Mineral and Supplements
category, one of the largest and fastest-growing consumer health
categories in the U.S.
Paris, July
28, 2023. Sanofi
announces today it has entered into a definitive agreement to
acquire ownership of Qunol®, a U.S.-based, market-leading brand in
health & wellness. This transaction will strengthen Sanofi’s
Consumer Healthcare’s (CHC) Vitamin, Mineral and Supplements (VMS)
category, one of the largest and fastest-growing consumer health
categories in the U.S., focusing on the active ‘healthy aging’
segment. With Qunol’s CoQ10 in heart health and Turmeric in joint
health, CHC at Sanofi adds a trusted, profitable double-digit
growth brand to its U.S. portfolio, focused on chronic conditions
with growing consumer demand. With this acquisition, Sanofi
continues to pursue growth opportunities and value creation for its
consumer healthcare business.
Julie Van OngevalleExecutive
Vice President, Consumer Healthcare, Sanofi“The acquisition of
Qunol further strengthens our portfolio in the wellness category.
It taps into the growing ‘healthy aging’ segment and fills one of
our white spaces in the US, unlocking an opportunity for us to
build on our U.S. presence and accelerate our growth. VMS now
functions as long-term support for overall health and wellness
where proactive preventive health has become the new norm
post-pandemic. We are excited to welcome Qunol and, with this
addition to our consumer healthcare portfolio, reinforce our
commitment to bring more health into the hands of people.”
Qunol CoQ10 and Turmeric products are both
backed by science literature and strong market positioning in their
segments. Qunol’s high product quality and efficacy have resulted
in strong brand equity among consumers and customers, as well as
above category consumer loyalty. The Qunol brand will benefit from
Sanofi’s CHC resources to expand into other chronic conditions and
develop its footprint outside the U.S.
Peter BoutrosCEO, Quten
Research Institute, LLC“Qunol is looking forward to joining
Sanofi’s consumer healthcare team and developing synergies that
will further drive brand awareness for our products with our
consumers and customers. With Sanofi, we have the opportunity to
further grow in the U.S. and beyond, tapping into Sanofi Consumer
Healthcare’s commercial breadth and strength.”
Transaction terms
Sanofi entered into a definitive agreement to
acquire ownership of Qunol, subject to customary closing
conditions, including applicable regulatory approvals. The
acquisition is expected to close Q3 2023.
About QunolFounded in 2006 with the goal of
delivering efficacious, science-backed health solutions, Qunol is a
market leader in the VMS industry and at the forefront of the
fast-growing healthy aging sector. The brand's CoQ10 and Turmeric
products are differentiated solutions that combine high-quality
ingredients with unique absorption technology to deliver powerful
support for heart health and joint health respectively. Qunol's
products enjoy multiple #1 market positions across leading Club,
Mass and Ecommerce retailers in North America.
About SanofiWe are an innovative global
healthcare company, driven by one purpose: we chase the miracles of
science to improve people’s lives. Our team, across some 100
countries, is dedicated to transforming the practice of medicine by
working to turn the impossible into the possible. We provide
potentially life-changing treatment options and life-saving vaccine
protection to millions of people globally, while putting
sustainability and social responsibility at the center of our
ambitions.
Sanofi is listed on EURONEXT: SAN and NASDAQ:
SNY
Media RelationsSandrine
Guendoul | + 33 6 25 09 14 25 |
sandrine.guendoul@sanofi.comEvan Berland | +1 215
432 0234 | evan.berland@sanofi.comVictor Rouault |
+ 33 6 70 93 71 40 | victor.rouault@sanofi.com
Investor RelationsEva
Schaefer-Jansen | + 33 7 86 80 56 39 |
eva.schaefer-jansen@sanofi.comArnaud
Delépine | + 33 6 73 69 36 93 |
arnaud.delepine@sanofi.comCorentine
Driancourt | + 33 6 40 56 92 21 |
corentine.driancourt@sanofi.comFelix
Lauscher | + 1 908 612 7239 |
felix.lauscher@sanofi.comTarik
Elgoutni| + 1 617 710 3587 |
tarik.elgoutni@sanofi.comNathalie Pham | + 33 7 85
93 30 17 | nathalie.pham@sanofi.com
Sanofi Forward-Looking
StatementsThis press release contains forward-looking
statements as defined in the Private Securities Litigation Reform
Act of 1995, as amended. Forward-looking statements are statements
that are not historical facts. These statements include projections
and estimates regarding the marketing and other potential of the
product, or regarding potential future revenues from the product.
Forward-looking statements are generally identified by the words
“expects”, “anticipates”, “believes”, “intends”, “estimates”,
“plans” and similar expressions. Although Sanofi’s management
believes that the expectations reflected in such forward-looking
statements are reasonable, investors are cautioned that
forward-looking information and statements are subject to various
risks and uncertainties, many of which are difficult to predict and
generally beyond the control of Sanofi, that could cause actual
results and developments to differ materially from those expressed
in, or implied or projected by, the forward-looking information and
statements. These risks and uncertainties include among other
things, unexpected regulatory actions or delays, or government
regulation generally, that could affect the availability or
commercial potential of the product, the fact that product may not
be commercially successful, risks related to Sanofi’s ability to
complete the acquisition on the proposed terms or on the proposed
timeline, including the receipt of required regulatory approvals,
the uncertainties inherent in research and development, including
future clinical data and analysis of existing clinical data
relating to the product, including post marketing, unexpected
safety, quality or manufacturing issues, competition in general,
risks associated with intellectual property and any related future
litigation and the ultimate outcome of such litigation, and
volatile economic and market conditions, and the impact that
pandemics or other global crises may have on us, our customers,
suppliers, vendors, and other business partners, and the financial
condition of any one of them, as well as on our employees and on
the global economy as a whole. The risks and uncertainties also
include the uncertainties discussed or identified in the public
filings with the SEC and the AMF made by Sanofi, including those
listed under “Risk Factors” and “Cautionary Statement Regarding
Forward-Looking Statements” in Sanofi’s annual report on Form 20-F
for the year ended December 31, 2022. Other than as required by
applicable law, Sanofi does not undertake any obligation to update
or revise any forward-looking information or statements.
Sanofi (EU:SAN)
Gráfico Histórico do Ativo
De Out 2023 até Nov 2023
Sanofi (EU:SAN)
Gráfico Histórico do Ativo
De Nov 2022 até Nov 2023
